Close Menu

NEW YORK (GenomeWeb) – Qiagen and NeuMoDx said today they have signed a strategic partnership and merger agreement related to the commercialization of a pair of fully integrated PCR-based molecular diagnostic systems.

As part of their strategic partnership, Qiagen will initially distribute the NeuMoDx 288 (high-throughput) and NeuMoDx 96 (mid-throughput) systems in Europe and other markets outside the US, where NeuMoDx will continue to market the products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.